ABUS Arbutus Biopharma Corporation

Name of reporting person

Dexxon Holdings Ltd.

Check the appropriate box if a member of a group

(a) ¨ (b) ¨

SEC use only

Source of funds

OO – other

Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) ¨

Citizenship or place of organization

Israel

Number of

shares

beneficially

owned by

each

reporting

person

with

Sole voting power

0

Shared voting power

0

Sole dispositive power

0

Shared dispositive power

16,013,540 Common Shares (see Item 5)

Aggregate amount beneficially owned by each reporting person

16,013,540 Common Shares (see Item 5)

Check box if the aggregate amount in Row (11) excludes certain shares ¨

Percent of class represented by amount in Row (11)

29.1% (see Item 5)*

Type of reporting person

CO

Name of reporting person

Dexcel Pharma Technologies Ltd.

Check the appropriate box if a member of a group

(a) ¨ (b) ¨

SEC use only

Source of funds

OO – other

Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) ¨

Citizenship or place of organization

Israel

Number of

shares

beneficially

owned by

each

reporting

person

with

Sole voting power

0

Shared voting power

0

Sole dispositive power

0

Shared dispositive power

16,013,540 Common Shares (see Item 5)

Aggregate amount beneficially owned by each reporting person

16,013,540 Common Shares (see Item 5)

Check box if the aggregate amount in Row (11) excludes certain shares ¨

Percent of class represented by amount in Row (11)

29.1% (see Item 5)*

Type of reporting person

CO

Name of reporting person

Dan Oren

Check the appropriate box if a member of a group

(a) ¨ (b) ¨

SEC use only

Source of funds

OO – other

Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) ¨

Citizenship or place of organization

Israel

Number of

shares

beneficially

owned by

each

reporting

person

with

Sole voting power

0

Shared voting power

0

Sole dispositive power

0

Shared dispositive power

16,013,540 Common Shares (see Item 5)

Aggregate amount beneficially owned by each reporting person

16,013,540 Common Shares (see Item 5)

Check box if the aggregate amount in Row (11) excludes certain shares ¨

Percent of class represented by amount in Row (11)

29.1% (see Item 5)*

Type of reporting person

IN

The Common Shares are directly beneficially owned by Roivant. The Reporting Persons may be deemed to have shared dispositive power, and therefore, beneficial ownership, over the 16,013,540 Common Shares owned directly by Roivant. Roivant’s bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant’s board of directors, including with respect to dispositions of the Preferred Shares (the “Override Right”). Each of Dexxon and DPT is a shareholder of Roivant and, collectively, are holders of the Override Right. Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment and voting control over the Common Shares held by Roivant.

Following the Second Closing on January 12, 2018, Roivant beneficially owns 16,013,540, or 29.1%, of the Common Shares. Roivant will not beneficially own the Common Shares underlying the Preferred Shares until the date that is 60 days prior to the date on which the Preferred Shares become convertible into the Common Shares, either automatically or at Roivant’s option pursuant to the terms of the Preferred Shares. As described in Item 6 of the Schedule 13D, the Preferred Shares will mandatorily convert into the Common Shares on the fourth anniversary of the First Closing (Ocotber 16, 2021), subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion at Roivant’s option.

The percentage of outstanding Common Shares that may be deemed to be beneficially owned by each Reporting Person is set forth on line 13 of the cover sheet of this Amendment. Such percentage was calculated based on an aggregate of 55,068,662 Common Shares issued and outstanding as of January 11, 2018, as provided by the Issuer to Roivant. This amount excludes 9,808,386 Common Shares underlying 500,000 Preferred Shares acquired by Roivant on October 16, 2017 and 13,025,536 Common Shares underlying 664,000 Preferred Shares acquired by Roivant on January 12, 2018. The Preferred Shares are not convertible into Common Shares until they become mandatorily convertible on the fourth anniversary of the First Closing (October 16, 2021) (subject to adjustment and subject to limited exceptions in the event of certain transactions or fundamental changes that would permit earlier conversion at Roivant's option). Therefore, the Common Shares underlying such Preferred Shares are not deemed beneficially owned, as described in this Item 5(a).

Except as disclosed in this Amendment, each Reporting Person does not have the right to acquire any Common Shares, and does not presently have the power to vote or to direct the vote or to dispose or direct the disposition of any of the Common Shares that the Reporting Person may be deemed to beneficially own.

Each of the Reporting Persons disclaims beneficial ownership in all of the Common Shares reported herein, except to the extent of the Reporting Person’s respective pecuniary interest therein. The filing of this Amendment shall not be construed as an admission that the Reporting Persons are, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended, the beneficial owners of the Common Shares.